BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 30, 2002
View Archived Issues
Marketing application filed in E.U. for Axcan's photodynamic therapy
Read More
Chymase inhibition in the spotlight
Read More
The role of endothelin blockade in organ transplantation
Read More
Studies on immunosuppression with FK-778 a highlight at Transplant 2002
Read More
Cellegy withdraws Cellegesic NDA
Read More
Lexicon Genetics discovers new oncogene for development of anticancer drugs
Read More
FDA alerts to Actos and Avandia label modifications
Read More
Transplant 2002: IDEC-131 improves transplant graft survival in combination regimens
Read More
Chinese herbal medicine improves I/R injury to the kidney via activation of eNOS
Read More
Drug used for xerostomia may help prevent lung cancer
Read More
Combination of antimetabolite and thymidine phosphorylase inhibitor in clinical development at Taiho
Read More
New selective partial agonist at D4 receptors designed at German university
Read More
Dihydropyridine Y1 receptor antagonists reduce food intake in rat models
Read More
LY-402913, a selective MRP1 inhibitor with in vivo resistance-modulating activity
Read More
Orally active thrombin inhibitor advances to phase II clinical trials at Boehringer Ingelheim
Read More
Aventis and Fujisawa form alliance for marketing of Synercid
Read More
Genta and Aventis collaborate on Genasense development and commercialization
Read More
Hyseq collaborations mark first quarter
Read More
DiAthegen and TissueInformatics form obesity and type 2 diabetes joint venture
Read More
Antex Biologics presents pipeline development plans
Read More
Neotrofin fails to meet primary endpoint in Alzheimer's disease
Read More
Selective estrogens with preference for the ERalpha receptor claimed by Jenapharm
Read More
Pharmacor presents new anti-HIV agents
Read More
Enantiomerically pure antiarrhythmic compounds prepared at ARYx
Read More
New protein farnesyltransferase inhibitors described by Schering-Plough
Read More
Recent patent covers synthesis and use of new inhibitors of proinflammatory cytokine production
Read More
Novel Takeda compounds claimed for use in heart failure, etc.
Read More